Squarepoint Ops LLC Has $3.62 Million Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Squarepoint Ops LLC boosted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 10.4% in the second quarter, HoldingsChannel reports. The firm owned 90,552 shares of the company’s stock after acquiring an additional 8,501 shares during the period. Squarepoint Ops LLC’s holdings in Amphastar Pharmaceuticals were worth $3,622,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of AMPH. Annex Advisory Services LLC raised its holdings in shares of Amphastar Pharmaceuticals by 213.2% in the fourth quarter. Annex Advisory Services LLC now owns 13,860 shares of the company’s stock valued at $857,000 after buying an additional 9,435 shares during the last quarter. Epoch Investment Partners Inc. raised its stake in shares of Amphastar Pharmaceuticals by 348.7% in the fourth quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock worth $36,648,000 after acquiring an additional 460,473 shares during the last quarter. Seven Eight Capital LP acquired a new position in shares of Amphastar Pharmaceuticals during the fourth quarter worth approximately $801,000. Shariaportfolio Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 8.5% in the fourth quarter. Shariaportfolio Inc. now owns 13,574 shares of the company’s stock valued at $840,000 after purchasing an additional 1,069 shares in the last quarter. Finally, Boone Capital Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $24,740,000. Institutional investors own 65.09% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $63.00.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the sale, the executive vice president now owns 118,388 shares of the company’s stock, valued at $5,724,059.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 4,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the sale, the executive vice president now directly owns 118,388 shares in the company, valued at $5,724,059.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO William J. Peters sold 10,282 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total value of $454,772.86. Following the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $4,162,175.69. The disclosure for this sale can be found here. Insiders have sold 34,383 shares of company stock valued at $1,524,123 in the last 90 days. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Stock Down 0.4 %

NASDAQ:AMPH opened at $48.35 on Wednesday. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The stock’s fifty day simple moving average is $45.55 and its 200-day simple moving average is $42.75. The firm has a market capitalization of $2.36 billion, a P/E ratio of 16.73, a P/E/G ratio of 0.92 and a beta of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. The firm had revenue of $182.39 million for the quarter, compared to analysts’ expectations of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. Equities research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.